8x8 Inc
Change company Symbol lookup
Select an option...
EGHT 8x8 Inc
REGI Renewable Energy Group Inc
MCK Mckesson Corp
CNBX Cannabics Pharmaceuticals Inc
BLK BlackRock Inc
FNMA Federal National Mortgage Association
MPW Medical Properties Trust Inc
PSXP Phillips 66 Partners LP
EQ Equillium Inc
TSLA Tesla Inc
Go

Information Technology : Software | Small Cap Growth
Company profile

8x8, Inc. provides cloud-based, enterprise-class software solutions. The Company's solutions are delivered through Software as a Service (SaaS) business model. Its segments include Americas and Europe. Its software platform brings together cloud, mobile, collaboration, video and data science technologies. Through a combination of open application program interface (API) and pre-built integrations, its solutions leverage critical customer context from internal data systems and customer relationship management (CRM) systems. Its software product, branded as 8x8 Virtual Office, delivers voice as a service across the world. 8x8 Virtual Office enables a customer to use a single business phone number to place and receive calls from any supported device. It provides software to enable a multi-channel contact center under the 8x8 Virtual Contact Center brand. Its Virtual Office Meetings software solution is a tool for teams within the enterprise to meet and collaborate on a shared project.

Closing Price
$17.28
Day's Change
-0.90 (-4.95%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.25
Day's Low
17.21
Volume
(Heavy Day)
Volume:
2,003,149

10-day average volume:
1,579,636
2,003,149

Study Shows Clinical Utility of the Prospera(TM) Test in Nephrology Practice

9:03 am ET September 1, 2020 (PR Newswire) Print

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a prospective, randomized controlled trial showing clinical utility of the Prospera test. The study concluded that practicing nephrologists who used the Prospera test detected more cases of rejection and made better clinical decisions than physicians in the control group. The study evaluated kidney transplant patients in typical scenarios seen by nephrologists in routine practice. The study was published in International Urology and Nephrology,1 and is available to read here.

https://mma.prnewswire.com/media/286881/Natera_Inc___Logo.jpg

"The Prospera test can be a vital tool in early detection and the treatment decision-making process of our patients," said Jessica Coleman, MD, Nephrologist at Beaufort Memorial Hospital. "When we evaluate patient scenarios with the Prospera test, we gain insights to help increase the chances of a successful transplant and improved outcomes."

The Prospera test's previously published clinical validation showed excellent performance in the detection of active kidney transplant rejection.2 This latest study measured the clinical practice of 154 nephrologists with and without dd-cfDNA testing. To determine whether the use of the Prospera test demonstrated overall clinical utility, 924 simulations were completed. The study, conducted by QURE Healthcare and researchers from a top academic institution, showed that those using the Prospera test to evaluate post-transplant patients were more likely to reach an early, accurate diagnosis and appropriately change their treatment compared to those using creatinine and other routine biomarkers alone.

Highlights of the study concluded:

-- Use of the Prospera test led to a 300 percent increase in probability of confirming rejection via biopsy in both routine and in ambiguous clinical scenarios.

-- Nephrologists using the Prospera test to identify rejection more than doubled the appropriate referrals to transplant centers and/or biopsies.

-- Prospera test results yielded a 137 percent improvement in treatment decisions that preserved kidney function.

"The results of this study provide valuable insights into the Prospera test's capabilities and utility in the nephrology practice," said Paul Billings, MD, PhD, Natera's Chief Medical Officer and a co-author on the study. "Results clearly show that the use of the Prospera test demonstrated clinical utility and improved care of the emulated patients through changes in diagnosis, workup, and management after kidney transplant."

About the Prospera dd-cfDNA Organ Transplant Test

The Prospera test leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. The Prospera test has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The Prospera test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

ContactsInvestor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com

References

-- Peabody J, Billings P, Valdenor C, et al. Randomized clinical trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal transplant patients. Int Urol Nephrol. 2020;52(8):1593-1601.

-- Sigdel TK, Archila FA, Constantin T, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2019;8(1):19.

https://c212.net/c/img/favicon.png?sn=SF12042&sd=2020-09-01

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-clinical-utility-of-the-prospera-test-in-nephrology-practice-301121659.html

SOURCE Natera, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=SF12042&Transmission_Id=202009010903PR_NEWS_USPR_____SF12042&DateId=20200901

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.